A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis

被引：23

作者：

Pica, Roberta ^{[1
]}

Cassieri, Claudio ^{[2
]}

Cocco, Andrea ^{[1
]}

Zippi, Maddalena ^{[1
]}

Marcheggiano, Adriana ^{[2
]}

De Nitto, Daniela ^{[1
]}

Avallone, Eleonora Veronica ^{[2
]}

Crispino, Pietro ^{[2
]}

Occhigrossi, Giuseppe ^{[1
]}

Paoluzi, Paolo ^{[2
]}

机构：

[1] Sandro Pertini Hosp, Div Gastroenterol & Digest Endoscopy, IBD Unit, I-00157 Rome, Italy

[2] Univ Rome, Gastroenterol Unit, Dept Internal Med & Med Specialties, Rome, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2015年 / 47卷 / 11期

关键词：

Daily dosage; Maintenance of remission; Mesalazine; Ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; 5-AMINOSALICYLIC ACID MESALAZINE; SELF-LIMITED COLITIS; MAINTAINING REMISSION; CROHNS-DISEASE; RECTAL BIOPSY; THERAPY; MESALAMINE; SULFASALAZINE; EFFICACY;

D O I：

10.1016/j.dld.2015.07.011

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Mesalazine is used as maintenance therapy in ulcerative colitis but the optimal dosage is still controversial. Aim: To compare the remission-maintenance efficacy and tolerability of two daily doses of oral mesalazine (4.8 g and 2.4 g) in patients with ulcerative colitis with frequent relapses in a randomized controlled trial. Methods: 112 ulcerative colitis patients in remission were enrolled and randomly allocated to treatment for 1 year with oral mesalazine at a daily dose of 4.8 g (n = 56, Group A) or 2.4 g (n = 56, Group B). Results: At the end of the 12 months, intention to treat analysis revealed persistent remission in 42 (75%) in Group A and 36 (64.2%) in Group B (p = 0.3). The higher daily dose (4.8 g) proved to be significantly more effective for maintaining remission in patients under 40 years of age (90.5% Group A vs. 50% Group B; Fisher's exact test, p = 0.0095) and in those with extensive disease (90.9% Group A vs. 46.7% Group B; Fisher's exact test, p = 0.0064). Conclusions: In ulcerative colitis patients younger than 40 years and/or with extensive disease, a daily dose of 4.8 g oral mesalazine results in increased rates and duration of remission compared to 2.4 g. (C) 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

页码：933 / 937

页数：5

共 28 条

[1]

ALLISON MC, 1987, Q J MED, V65, P985

[2]

Ardizzone S, 1999, ALIMENT PHARM THERAP, V13, P373

[3] VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS [J].

BARON, JH ;

CONNELL, AM ;

LENNARDJONES, JE .

BRITISH MEDICAL JOURNAL, 1964, 1 (5374) :89-+

[4] How effective are the usual treatments for Crohn's disease? [J].

Bebb, JR ;

Scott, BB .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (02) :151-159

[5] Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis [J].

Bitton, A ;

Peppercorn, MA ;

Antonioli, DA ;

Niles, JL ;

Shah, S ;

Bousvaros, A ;

Ransil, B ;

Wild, G ;

Cohen, A ;

Edwardes, MDD ;

Stevens, AC .

GASTROENTEROLOGY, 2001, 120 (01) :13-20

[6] CLINICAL-APPEARANCE AT DIAGNOSIS OF ULCERATIVE-COLITIS AND CROHNS-DISEASE IN A REGIONAL PATIENT GROUP [J].

BOTH, H ;

TORPPEDERSEN, K ;

KREINER, S ;

HENDRIKSEN, C ;

BINDER, V .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1983, 18 (07) :987-991

[7]

dAlbasio G, 1997, AM J GASTROENTEROL, V92, P1143

[8] MAINTENANCE OF REMISSION IN ULCERATIVE-COLITIS WITH 5-AMINO SALICYLIC-ACID IN HIGH-DOSES BY MOUTH [J].

DEW, MJ ;

HARRIES, AD ;

EVANS, N ;

EVANS, BK ;

RHODES, J .

BRITISH MEDICAL JOURNAL, 1983, 287 (6384) :23-24

[9] MAINTENANCE OF REMISSION IN ULCERATIVE-COLITIS WITH ORAL PREPARATION OF 5-AMINOSALICYLIC ACID [J].

DEW, MJ ;

HUGHES, P ;

HARRIES, AD ;

WILLIAMS, G ;

EVANS, BK ;

RHODES, J .

BMJ-BRITISH MEDICAL JOURNAL, 1982, 285 (6347) :1012-1012

[10] Maintenance therapy for inflammatory bowel disease [J].

Feagan, BG .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) :S6-S17

← 1 2 3 →